Adaptin Bio (APTN) Consolidated Net Income (2023 - 2026)

Adaptin Bio (APTN) has 4 years of Consolidated Net Income data on file, last reported at -$1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income fell 90.04% year-over-year to -$1.1 million; the trailing twelve-month figure through Mar 2026 stood at -$5.7 million (down 69.77% YoY), and the FY2025 full-year result was -$4.1 million, down 67.02% from the prior year.
• Consolidated Net Income improved to -$1.1 million in Q1 2026, from -$1.4 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of -$42938.0 in Q3 2023 to a low of -$1.7 million in Q3 2025.
• A 4-year average of -$866017.1 and a median of -$834279.0 in 2024 frame the typical range for Consolidated Net Income.
• Across the five-year window, Consolidated Net Income slumped 2479.42% in 2024 and sank 51.29% in 2025, its largest moves.
• Tracing APTN's Consolidated Net Income over 4 years: stood at -$69585.0 in 2023, then plunged by 1098.94% to -$834279.0 in 2024, then plunged by 63.98% to -$1.4 million in 2025, then gained by 16.22% to -$1.1 million in 2026.
• Business Quant data shows APTN's Consolidated Net Income at -$1.1 million in Q1 2026, -$1.4 million in Q4 2025, and -$1.7 million in Q3 2025.